JP2018090504A - Muscle enhancing composition - Google Patents
Muscle enhancing composition Download PDFInfo
- Publication number
- JP2018090504A JP2018090504A JP2016233127A JP2016233127A JP2018090504A JP 2018090504 A JP2018090504 A JP 2018090504A JP 2016233127 A JP2016233127 A JP 2016233127A JP 2016233127 A JP2016233127 A JP 2016233127A JP 2018090504 A JP2018090504 A JP 2018090504A
- Authority
- JP
- Japan
- Prior art keywords
- muscle
- composition
- salt
- extract
- hmb
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000003205 muscle Anatomy 0.000 title claims abstract description 80
- 239000000203 mixture Substances 0.000 title claims abstract description 69
- 230000002708 enhancing effect Effects 0.000 title claims abstract description 26
- AXFYFNCPONWUHW-UHFFFAOYSA-N 3-hydroxyisovaleric acid Chemical compound CC(C)(O)CC(O)=O AXFYFNCPONWUHW-UHFFFAOYSA-N 0.000 claims abstract description 112
- 235000020095 red wine Nutrition 0.000 claims abstract description 35
- 241000234314 Zingiber Species 0.000 claims abstract description 32
- 235000006886 Zingiber officinale Nutrition 0.000 claims abstract description 32
- 235000008397 ginger Nutrition 0.000 claims abstract description 32
- 239000000284 extract Substances 0.000 claims abstract description 31
- 150000003839 salts Chemical class 0.000 claims abstract description 31
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 claims abstract description 25
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 claims abstract description 23
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 claims abstract description 23
- 229960003104 ornithine Drugs 0.000 claims abstract description 23
- 238000005728 strengthening Methods 0.000 claims description 22
- 230000004220 muscle function Effects 0.000 abstract description 10
- 230000000694 effects Effects 0.000 abstract description 9
- 230000001965 increasing effect Effects 0.000 abstract description 8
- 230000007423 decrease Effects 0.000 abstract description 6
- 206010049565 Muscle fatigue Diseases 0.000 abstract description 4
- 230000015556 catabolic process Effects 0.000 abstract description 4
- 201000010099 disease Diseases 0.000 abstract description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 4
- 230000006872 improvement Effects 0.000 abstract description 3
- 238000007665 sagging Methods 0.000 abstract description 3
- 208000024891 symptom Diseases 0.000 abstract description 3
- 208000001132 Osteoporosis Diseases 0.000 abstract description 2
- 238000011084 recovery Methods 0.000 abstract description 2
- 208000001076 sarcopenia Diseases 0.000 abstract description 2
- 238000012549 training Methods 0.000 abstract description 2
- 230000037303 wrinkles Effects 0.000 abstract description 2
- 206010040954 Skin wrinkling Diseases 0.000 abstract 1
- 230000003247 decreasing effect Effects 0.000 abstract 1
- 235000018823 dietary intake Nutrition 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 230000014509 gene expression Effects 0.000 description 17
- 102000004364 Myogenin Human genes 0.000 description 13
- 108010056785 Myogenin Proteins 0.000 description 13
- 230000009471 action Effects 0.000 description 12
- 235000013305 food Nutrition 0.000 description 11
- 238000012360 testing method Methods 0.000 description 11
- 235000013361 beverage Nutrition 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- 238000004519 manufacturing process Methods 0.000 description 9
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 8
- 230000004069 differentiation Effects 0.000 description 8
- 108020004999 messenger RNA Proteins 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 7
- 239000000843 powder Substances 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 239000004615 ingredient Substances 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 239000002537 cosmetic Substances 0.000 description 5
- 238000001035 drying Methods 0.000 description 5
- 238000000605 extraction Methods 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 230000006698 induction Effects 0.000 description 5
- 210000000663 muscle cell Anatomy 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
- 101100447432 Danio rerio gapdh-2 gene Proteins 0.000 description 4
- 101150112014 Gapdh gene Proteins 0.000 description 4
- 235000013376 functional food Nutrition 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 210000003098 myoblast Anatomy 0.000 description 4
- 230000008439 repair process Effects 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 159000000007 calcium salts Chemical class 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 230000000378 dietary effect Effects 0.000 description 3
- 235000013402 health food Nutrition 0.000 description 3
- 239000006210 lotion Substances 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 230000009756 muscle regeneration Effects 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000003270 steroid hormone Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 208000010428 Muscle Weakness Diseases 0.000 description 2
- 206010028372 Muscular weakness Diseases 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 238000011529 RT qPCR Methods 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 159000000009 barium salts Chemical class 0.000 description 2
- JRFZSUMZAUHNSL-UHFFFAOYSA-N chrysin 5,7-dimethyl ether Chemical compound C=1C(OC)=CC(OC)=C(C(C=2)=O)C=1OC=2C1=CC=CC=C1 JRFZSUMZAUHNSL-UHFFFAOYSA-N 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 230000006866 deterioration Effects 0.000 description 2
- 235000015872 dietary supplement Nutrition 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000000469 ethanolic extract Substances 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 235000020510 functional beverage Nutrition 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000007902 hard capsule Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- GWYFCOCPABKNJV-UHFFFAOYSA-N isovaleric acid Chemical compound CC(C)CC(O)=O GWYFCOCPABKNJV-UHFFFAOYSA-N 0.000 description 2
- 239000011344 liquid material Substances 0.000 description 2
- 229910003002 lithium salt Inorganic materials 0.000 description 2
- 159000000002 lithium salts Chemical class 0.000 description 2
- 159000000003 magnesium salts Chemical class 0.000 description 2
- 239000012046 mixed solvent Substances 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 159000000000 sodium salts Chemical class 0.000 description 2
- 239000007901 soft capsule Substances 0.000 description 2
- 239000008247 solid mixture Substances 0.000 description 2
- 238000001694 spray drying Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 235000014101 wine Nutrition 0.000 description 2
- IAFBOKYTDSDNHV-UHFFFAOYSA-N (2S)-(-)-5,7-dimethoxyflavanone Natural products O1C2=CC(OC)=CC(OC)=C2C(=O)CC1C1=CC=CC=C1 IAFBOKYTDSDNHV-UHFFFAOYSA-N 0.000 description 1
- GGTYBZJRPHEQDG-WCCKRBBISA-N (2s)-2,5-diaminopentanoic acid hydrochloride Chemical compound Cl.NCCC[C@H](N)C(O)=O GGTYBZJRPHEQDG-WCCKRBBISA-N 0.000 description 1
- GWYFCOCPABKNJV-UHFFFAOYSA-M 3-Methylbutanoic acid Natural products CC(C)CC([O-])=O GWYFCOCPABKNJV-UHFFFAOYSA-M 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 101100239693 Dictyostelium discoideum myoD gene Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 108091092584 GDNA Proteins 0.000 description 1
- 241000395050 Kaempferia parviflora Species 0.000 description 1
- 101150094019 MYOG gene Proteins 0.000 description 1
- 208000034819 Mobility Limitation Diseases 0.000 description 1
- 208000016285 Movement disease Diseases 0.000 description 1
- 206010028289 Muscle atrophy Diseases 0.000 description 1
- 238000009004 PCR Kit Methods 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 238000011530 RNeasy Mini Kit Methods 0.000 description 1
- 101001023030 Toxoplasma gondii Myosin-D Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 235000013532 brandy Nutrition 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 239000007894 caplet Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000008278 cosmetic cream Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 229940002508 ginger extract Drugs 0.000 description 1
- 235000020708 ginger extract Nutrition 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 235000019674 grape juice Nutrition 0.000 description 1
- 235000001497 healthy food Nutrition 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229910017053 inorganic salt Inorganic materials 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 235000020045 marsala Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 1
- 230000020763 muscle atrophy Effects 0.000 description 1
- 210000003130 muscle precursor cell Anatomy 0.000 description 1
- 201000000585 muscular atrophy Diseases 0.000 description 1
- 210000001087 myotubule Anatomy 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 108091008025 regulatory factors Proteins 0.000 description 1
- 102000037983 regulatory factors Human genes 0.000 description 1
- -1 round Shapes Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000002453 shampoo Substances 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 235000020047 vermouth Nutrition 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
本発明は、筋肉増強用組成物に関する。 The present invention relates to a composition for enhancing muscles.
加齢、運動不足、運動の不能などにより筋機能が低下すると、歩行が困難になるなど、通常の生活を営む上で支障を来すことになる。さらに、筋肉量の減少は、皺やたるみなどの美容上の問題に発展する場合がある。 If muscle function declines due to aging, lack of exercise, or inability to exercise, walking will be difficult, leading to difficulties in running a normal life. Furthermore, the loss of muscle mass may develop into cosmetic problems such as wrinkles and sagging.
そこで、筋肉量の減少、筋肉の分解、筋肉疲労、運動能力の低下といった筋機能低下を予防改善又は緩和するものとして、筋肉増強作用を有する成分や該成分を含有する組成物が望まれている。例えば、筋肉増強作用を有する化合物としては、ステロイドホルモンが知られている。しかし、ステロイドホルモンを摂取することにより、循環器疾患などの重篤な副作用が生じることが知られている。 Therefore, a component having a muscle strengthening action and a composition containing the component are desired as preventive improvement or alleviation of muscle function deterioration such as muscle mass reduction, muscle degradation, muscle fatigue, and lowering of exercise ability. . For example, steroid hormones are known as compounds having a muscle enhancing action. However, it is known that taking steroid hormones causes serious side effects such as cardiovascular diseases.
筋肉細胞の分化は、ミオゲニン、myoDなどの筋制御因子(muscle regulatory factors;MRFs)によって調節される。MyoDを発端として、ミオゲニンが発現することにより、下流のカスケードが機能して、間葉系幹細胞は筋肉細胞へと分化する。筋肉細胞の分化を経た筋肉の再生は、老化又は慢性炎症に起因する筋委縮症を改善又は緩和することが期待できる。 Muscle cell differentiation is regulated by muscle regulatory factors (MRFs) such as myogenin and myoD. When myogenin is expressed starting from MyoD, the downstream cascade functions to differentiate mesenchymal stem cells into muscle cells. Regeneration of muscle through differentiation of muscle cells can be expected to improve or alleviate muscle atrophy resulting from aging or chronic inflammation.
筋肉の再生及び修復に有用な成分として、β−ヒドロキシ−β−メチル酪酸(HMB)が知られている。例えば、特許文献1には、HMBを摂取することにより、筋肉の再生及び修復に関与する筋肉前駆体細胞が活性化及び分化され、次いで筋線維へ融合することにより、新しい筋核が既存の筋線維内に見出されることが記載されている。 As a component useful for muscle regeneration and repair, β-hydroxy-β-methylbutyric acid (HMB) is known. For example, Patent Document 1 discloses that, by ingesting HMB, muscle precursor cells involved in muscle regeneration and repair are activated and differentiated, and then fused to muscle fibers, so that a new myonucleus is added to the existing muscle. It is described to be found in the fibers.
しかし、本発明者らが調べたところによれば、HMBが有する筋肉細胞への分化誘導などの筋肉増強作用は十分とはいえない。また、ステロイドホルモンとは異なり、筋肉増強作用が高いながらも、重篤な副作用が生じない成分はこれまでに知られていない。 However, according to the investigations by the present inventors, it cannot be said that HMB has a muscle strengthening action such as induction of differentiation into muscle cells. Further, unlike steroid hormones, no ingredient has been known so far that has a high muscle strengthening action but does not cause serious side effects.
そこで、本発明は、筋肉増強作用が高く、かつ、副作用の生じることが低減された成分を含有する筋肉増強用組成物を提供することを、本発明が解決しようとする課題とする。 Therefore, an object of the present invention is to provide a muscle strengthening composition containing a component having a high muscle strengthening action and reduced side effects.
本発明者らは、上記課題を解決するために、種々の成分、とりわけ食経験のある成分について鋭意検討を積み重ねた結果、驚くべきことに、単独の摂取では筋肉増強作用が十分とはいえないHMBを、特定の成分と組み合わせたところ、大きな筋肉増強作用を示すことを見出した。しかも、その作用の程度はHMBを単独で用いた場合に比べて顕著に大きかったことから、HMBと特定の成分とを組み合わせることによって得られる筋肉増強作用は、相加的というよりもむしろ相乗的な作用であった。 In order to solve the above-mentioned problems, the present inventors have intensively studied various ingredients, particularly ingredients having a dietary experience. As a result, surprisingly, it cannot be said that the muscle-enhancing effect is sufficient when taken alone. It has been found that when HMB is combined with specific components, it exhibits a large muscle-enhancing effect. Moreover, since the degree of action was significantly greater than when HMB was used alone, the muscle strengthening action obtained by combining HMB with a specific component was synergistic rather than additive. It was an effect.
その結果として、本発明者らは、筋肉増強用組成物として、HMBと、食経験のある特定の成分とを含有する組成物の創作に成功した。本発明は、かかる知見や成功例に基づいて完成された発明である。 As a result, the present inventors have succeeded in creating a composition containing HMB and a specific ingredient with a dietary experience as a muscle strengthening composition. The present invention has been completed on the basis of such knowledge and successful examples.
したがって、本発明によれば、以下[1]〜[3]の筋肉増強用組成物が提供される。
[1]β−ヒドロキシ−β−メチル酪酸及び/又はその塩と、赤ワイン及びその抽出物、黒ショウガ及びその抽出物、並びにオルニチン及びその塩からなる群から選ばれる2種以上の成分とを含有する、筋肉増強用組成物。
[2]β−ヒドロキシ−β−メチル酪酸及び/又はその塩と、赤ワイン及び/又はその抽出物と、黒ショウガ及び/又はその抽出物と、オルニチン及び/又はその塩とを含有する、筋肉増強用組成物。
[3]β−ヒドロキシ−β−メチル酪酸及び/又はその塩と、赤ワイン及びその抽出物、並びに黒ショウガ及びその抽出物のいずれか1種以上の成分とを含有する、筋肉増強用組成物。
Therefore, according to the present invention, the following compositions [1] to [3] are provided.
[1] Contains β-hydroxy-β-methylbutyric acid and / or salt thereof, and two or more components selected from the group consisting of red wine and extract thereof, black ginger and extract thereof, and ornithine and salt thereof A composition for strengthening muscles.
[2] Muscle enhancement containing β-hydroxy-β-methylbutyric acid and / or its salt, red wine and / or its extract, black ginger and / or its extract, and ornithine and / or its salt Composition.
[3] A composition for enhancing muscle, comprising β-hydroxy-β-methylbutyric acid and / or a salt thereof, and one or more components of red wine and an extract thereof, and black ginger and an extract thereof.
本発明の一態様の筋肉増強用組成物は、有効成分がいずれも食経験のある成分であり、摂取するに際して安全でありながら、高度な筋肉増強作用を示すことができる。本発明の一態様の筋肉増強用組成物は、このような作用を有することにより、筋肉量の減少、筋肉の分解、筋肉疲労、運動能力の低下といった筋機能低下や該筋機能低下によってもたらされる種々の症状や疾患、例えば、サルコペニア、骨粗鬆症、皺、たるみなどを改善、緩和、回復、治療又は予防することが期待できるばかりでなく、筋肉量増大、筋力上昇、シェイプアップ、痩身といった、筋機能の増強や身体の引き締めなどの要望にも応えることが期待できる。 In the composition for enhancing muscles of one embodiment of the present invention, the active ingredients are all ingredients that have dietary experience, and can exhibit a high degree of muscle strengthening action while being safe when ingested. The composition for enhancing muscles according to one embodiment of the present invention has such an action, and is thereby brought about by a decrease in muscle function such as a decrease in muscle mass, muscle degradation, muscle fatigue, and a decrease in exercise ability, or the decrease in muscle function. Not only can it be expected to improve, relieve, recover, treat or prevent various symptoms and diseases such as sarcopenia, osteoporosis, epilepsy, sagging, but also muscle function such as increased muscle mass, increased strength, shape up, slimming It can be expected to meet demands such as strengthening and tightening the body.
以下、本発明の一態様である筋肉増強用組成物の詳細について説明するが、本発明の技術的範囲は本項目の事項によってのみに限定されるものではなく、本発明はその目的を達成する限りにおいて種々の態様をとり得る。 Hereinafter, although the detail of the composition for muscle enhancement which is one aspect | mode of this invention is demonstrated, the technical scope of this invention is not limited only by the matter of this item, and this invention achieves the objective. As long as it can take various forms.
筋肉増強用組成物は、β−ヒドロキシ−β−メチル酪酸(HMB)及び/又はその塩、すなわち、HMB、HMBの塩又はこれらの両方を少なくとも含有する。 The muscle building composition contains at least β-hydroxy-β-methylbutyric acid (HMB) and / or a salt thereof, that is, HMB, a salt of HMB, or both.
HMBは、通常知られているとおりの、3−ヒドロキシイソ吉草酸ともよばれ、3−メチルブタン酸のβ位の炭素にヒドロキシル基が付加した構造を有するものである。HMBの塩は、通常知られているとおりのHMBの無機塩及び有機塩であれば特に限定されないが、例えば、HMBのカルシウム塩、マグネシウム塩、バリウム塩、ナトリウム塩、カリウム塩、リチウム塩といった金属塩などが挙げられ、好ましくはHMBのカルシウム塩である。 HMB, also known as 3-hydroxyisovaleric acid, has a structure in which a hydroxyl group is added to the β-position carbon of 3-methylbutanoic acid. The salt of HMB is not particularly limited as long as it is a commonly known inorganic salt and organic salt of HMB. For example, a metal such as calcium salt, magnesium salt, barium salt, sodium salt, potassium salt, lithium salt of HMB Salt, and the like, preferably calcium salt of HMB.
筋肉増強用組成物は、HMB及び/又はその塩に加えて、さらに特定の成分(以下、「副成分」ともよぶ。)を少なくとも含有する。筋肉増強用組成物は、含有する副成分が以下(1)〜(3)の態様をとり得ることによって、それぞれ互いに区別される:
(1)赤ワイン及びその抽出物、黒ショウガ及びその抽出物、並びにオルニチン及びその塩からなる群から選ばれる2種以上の成分
(2)赤ワイン及び/又はその抽出物、黒ショウガ及び/又はその抽出物、並びにオルニチン及び/又はその塩
(3)赤ワイン及びその抽出物、並びに黒ショウガ及びその抽出物のいずれか1種以上の成分
In addition to HMB and / or a salt thereof, the composition for enhancing muscle further contains at least a specific component (hereinafter also referred to as “subcomponent”). The muscle building compositions are distinguished from each other by the fact that the contained subcomponents can take the following aspects (1) to (3):
(1) Two or more components selected from the group consisting of red wine and its extract, black ginger and its extract, and ornithine and its salt (2) Red wine and / or its extract, black ginger and / or its extraction Ornithine and / or its salt (3) Red wine and its extract, and black ginger and its extract
赤ワインは、通常知られているとおりのブドウの果汁を発酵処理に供し、必要に応じて貯蔵して得られるものであれば特に限定されない。赤ワインは、赤ワインに種々の成分が添加されたものであってもよく、そのようなものとしては、例えば、濃縮果汁、ブランデーを添加したシェリー、ポート、マディラ、マラガ、マルサラなどのいわゆる補強ワイン、赤ワインに薬草、香料、色素などを添加して得られる、ベルモットを代表とする混成ワインなどが挙げられる。 The red wine is not particularly limited as long as it is obtained by subjecting grape juice to a fermentation treatment as is generally known and storing it as necessary. The red wine may be one in which various components are added to the red wine, such as concentrated fruit juice, soy with added brandy, Port, Madilla, Malaga, Marsala and so-called reinforced wine, Examples include mixed wines such as vermouth, which are obtained by adding medicinal herbs, fragrances, and pigments to red wine.
黒ショウガ(Kaempferia parviflora)は、東南アジアなどに自生することで知られているショウガ科バンウコン属の植物として知られているものであれば特に限定されず、例えば、その根、茎、葉、花、枝などの部位を用いることができるが、好ましくは根及び茎である。 The black ginger ( Kaempferia parviflora ) is not particularly limited as long as it is known as a plant belonging to the genus Vanucum, which is known to grow naturally in Southeast Asia and the like, for example, its root, stem, leaf, flower, Sites such as branches can be used, but roots and stems are preferred.
黒ショウガは、採取した状態の未加工のものに加えて、採取した後に所定の処理に供して得られる加工物であってもよい。加工物としては、例えば、乾燥粉末、細片化物及びその乾燥粉末、搾汁及びその乾燥粉末、抽出物及びその乾燥粉末などが挙げられるが、これらに限定されない。具体的には、加工、貯蔵、運搬などの容易性や使用形態の汎用性といった観点から、乾燥粉末であることが好ましい。 The black ginger may be a processed product obtained by subjecting it to a predetermined treatment after being collected, in addition to the unprocessed one in the collected state. Examples of the processed product include, but are not limited to, a dry powder, a fragmented product and a dry powder thereof, a juice and a dry powder thereof, an extract and a dry powder thereof. Specifically, a dry powder is preferable from the viewpoint of ease of processing, storage, transportation, etc. and versatility of usage forms.
赤ワインの抽出物及び黒ショウガの抽出物は、赤ワインや黒ショウガにおける成分が抽出された物であれば特に限定されないが、例えば、赤ワインや黒ショウガが含有する成分を、常法に従って溶媒で抽出して得られる抽出液、その希釈液や濃縮液、又はそれらの乾燥物やその粉末などが挙げられる。例えば、赤ワインが含有する成分としてはポリフェノールなどが挙げられ、黒ショウガが含有する成分としては5,7−ジメトキシフラボンといったポリメトキシフラボノイドなどが挙げられるが、これらに限定されない。 The extract of red wine and black ginger is not particularly limited as long as the components in red wine and black ginger are extracted. For example, the components contained in red wine and black ginger are extracted with a solvent in accordance with a conventional method. Extract, the diluted solution or concentrated solution thereof, or the dried product or powder thereof. For example, examples of the component contained in red wine include polyphenols, and examples of the component contained in black ginger include polymethoxyflavonoids such as 5,7-dimethoxyflavone, but are not limited thereto.
抽出に使用される溶媒としては、例えば、常温水、温水、熱水などの水;エタノール、メタノール、イソプロパノール、ブタノールなどの低級アルコール;酢酸エチル、酢酸メチルなどの低級エステル;アセトン;これらと水との混合溶媒などが挙げられる。混合溶媒としては、例えば、アセトン/水(2/8〜8/2、体積比)混合物、エタノール/水(2/8〜8/2、体積比)混合物などが挙げられる。 Examples of the solvent used for the extraction include water such as normal temperature water, warm water, and hot water; lower alcohols such as ethanol, methanol, isopropanol, and butanol; lower esters such as ethyl acetate and methyl acetate; acetone; Or a mixed solvent thereof. Examples of the mixed solvent include acetone / water (2/8 to 8/2, volume ratio) mixture, ethanol / water (2/8 to 8/2, volume ratio) mixture, and the like.
抽出方法は特に限定されないが、例えば、赤ワインや黒ショウガに対して2〜20倍質量の溶媒を加え、0℃〜溶媒の還流温度の範囲で数分〜数十時間、静置、振盪、攪拌、還流などの任意の条件下にて抽出を行う方法などが挙げられる。抽出作業後、ろ過、遠心分離などの固液分離操作を行い、不溶な固形物を除去することが好ましい。これに、必要に応じて希釈、濃縮などの操作を行うことにより、抽出物を得ることができる。さらに、不溶物についても同じ操作を繰り返して抽出し、その抽出物を先の抽出物と合わせて用いてもよい。これらの抽出物は、当業者が通常用いる精製方法により、さらに精製して使用してもよい。 The extraction method is not particularly limited. For example, a solvent having a mass of 2 to 20 times is added to red wine or black ginger, and the mixture is allowed to stand, shake, and stir for several minutes to several tens of hours in the range of 0 ° C. to the reflux temperature of the solvent. And a method of performing extraction under an arbitrary condition such as reflux. After the extraction operation, it is preferable to perform solid-liquid separation operations such as filtration and centrifugation to remove insoluble solid matter. An extract can be obtained by performing operations such as dilution and concentration as necessary. Further, the same operation may be repeated for insoluble matter, and the extract may be used in combination with the previous extract. These extracts may be used after further purification by a purification method commonly used by those skilled in the art.
抽出物から乾燥物を得る方法は特に限定されず、例えば、抽出物やその濃縮物を、噴霧乾燥、凍結乾燥、減圧乾燥、流動乾燥などの当業者が通常用いる乾燥処理に供する方法などが挙げられる。さらに、このようにして得られた乾燥物を、当業者に知られる方法を用いて粉末化して使用することが可能である。 A method for obtaining a dried product from the extract is not particularly limited, and examples thereof include a method of subjecting the extract and its concentrate to a drying process commonly used by those skilled in the art, such as spray drying, freeze drying, drying under reduced pressure, and fluidized drying. It is done. Furthermore, the dried product thus obtained can be used after being pulverized by a method known to those skilled in the art.
オルニチンは、通常知られているとおりの、2,5−ジアミノペンタン酸ともよばれるアミノ酸の1種である。オルニチンの塩は、通常知られているとおりのオルニチンの無機塩及び有機塩であれば特に限定されないが、例えば、オルニチンのカルシウム塩、マグネシウム塩、バリウム塩、ナトリウム塩、カリウム塩、リチウム塩といった金属塩などが挙げられる。 Ornithine is a kind of amino acid called 2,5-diaminopentanoic acid, as is generally known. The salt of ornithine is not particularly limited as long as it is an inorganic or organic salt of ornithine as is generally known. For example, a metal such as calcium salt, magnesium salt, barium salt, sodium salt, potassium salt, or lithium salt of ornithine. Examples include salt.
HMB及びその塩、赤ワイン及びその抽出物、黒ショウガ及びその抽出物、並びにオルニチン及びその塩のそれぞれは、当業者により通常知られている方法によって製造したものでもよいし、市場に流通しているものであってもよい。 Each of HMB and its salt, red wine and its extract, black ginger and its extract, and ornithine and its salt may be produced by a method usually known by those skilled in the art or distributed in the market. It may be a thing.
筋肉増強用組成物は、HMB及び/又はその塩と上記態様(1)〜(3)の副成分とを組み合わせて含有することによって、筋肉増強作用を示す。本明細書における「筋肉増強作用」とは、例えば、筋芽細胞の分化誘導、筋肉の再生や修復、筋肉量の増加、筋肉の分解抑制、筋肉疲労の回復促進及び運動能力向上のうち少なくともいずれか1つの作用をいう。筋肉増強用組成物は、後述する実施例に記載があるとおり、筋芽細胞によるミオゲニンの発現量が増大することによって、筋肉細胞の分化を経て筋肉の再生や修復をなし得る。 The composition for enhancing muscle exhibits a muscle enhancing action by containing HMB and / or a salt thereof in combination with the subcomponents of the above aspects (1) to (3). As used herein, the term “muscle enhancing action” refers to, for example, at least one of induction of myoblast differentiation, muscle regeneration and repair, increase in muscle mass, inhibition of muscle degradation, promotion of recovery from muscle fatigue, and improvement of exercise capacity. Or one action. As described in the examples described later, the muscle-enhancing composition can regenerate or repair muscle through differentiation of muscle cells by increasing the expression level of myogenin by myoblasts.
筋肉増強用組成物が有する筋肉増強作用の程度は、例えば、後述する実施例に記載があるとおりの細胞株を用いてin vitroにてミオゲニンの発現量を調べた場合に、ミオゲニンの発現量がHMBを単独で用いた場合よりも大きくなる程度であることが挙げられ、好ましくはHMBを単独で用いた場合に対して1.1倍以上であり、より好ましくはHMBを単独で用いた場合に対して1.5倍以上であり、さらに好ましくはHMBを単独で用いた場合に対して2.0倍以上であり、なおさらに好ましくはHMBを単独で用いた場合に対して2.5倍以上である。 The degree of muscle enhancing action of the composition for enhancing muscles is determined, for example, by examining the expression level of myogenin in vitro using a cell line as described in the examples described later. It is mentioned that it is a grade which becomes larger than the case where HMB is used independently, Preferably it is 1.1 times or more with respect to the case where HMB is used alone, More preferably, when HMB is used alone In contrast, it is 1.5 times or more, more preferably 2.0 times or more when HMB is used alone, and still more preferably 2.5 times or more when HMB is used alone. It is.
筋肉増強用組成物の製造方法は特に限定されず、例えば、室温や加温下で、各成分を含有せしめることにより、固形状組成物とすることができる。または、この固形状組成物を、水などの溶媒に溶解させて液状組成物とすることができる。さらに、各成分の液状物に、他の固形状成分を加えて混合することにより液状組成物とすることができる。なお、得られた液状組成物は、乾燥処理を経て、粉末化しても良い。この場合の乾燥処理の方法としては、噴霧乾燥、凍結乾燥などが挙げられるが、これらに限定されない。 The manufacturing method of the composition for muscle enhancement is not specifically limited, For example, it can be set as a solid composition by including each component at room temperature or under heating. Alternatively, this solid composition can be dissolved in a solvent such as water to form a liquid composition. Furthermore, it can be set as a liquid composition by adding and mixing another solid component to the liquid material of each component. In addition, you may pulverize the obtained liquid composition through a drying process. Examples of the drying process in this case include spray drying and freeze drying, but are not limited thereto.
筋肉増強用組成物に含有されるHMB及び/又はその塩並びに上記態様(1)〜(3)の副成分の含有量は、筋肉増強作用が認められる程度の量であれば特に限定されないが、経口用組成物としての下限値は、例えば、組成物全体に対して、0.0001wt%以上、好ましくは0.001wt%以上、より好ましくは0.01wt%以上であり、上限値は99wt%以下、好ましくは95wt%以下、より好ましくは90wt%以下である。化粧品などの非経口用組成物として下限値は、例えば、0.00001wt%以上、好ましくは0.0001wt%以上、より好ましくは0.001wt%以上であり、上限値は90wt%以下、好ましくは80wt%以下、より好ましくは70wt%以下である。 The content of HMB and / or a salt thereof contained in the composition for enhancing muscles and the accessory ingredients of the above aspects (1) to (3) is not particularly limited as long as the muscle enhancing action is recognized. The lower limit value as an oral composition is, for example, 0.0001 wt% or more, preferably 0.001 wt% or more, more preferably 0.01 wt% or more, and the upper limit value is 99 wt% or less with respect to the entire composition. , Preferably 95 wt% or less, more preferably 90 wt% or less. The lower limit of a parenteral composition such as cosmetics is, for example, 0.00001 wt% or more, preferably 0.0001 wt% or more, more preferably 0.001 wt% or more, and the upper limit is 90 wt% or less, preferably 80 wt%. % Or less, more preferably 70 wt% or less.
筋肉増強用組成物は、筋肉増強作用を得ることを目的とした種々の形態で利用され得る。例えば、特別な処理を加えることなく種々の目的に利用してもよい。筋肉増強用組成物を経口用として用いる場合、剤形は特に限定されないが、例えば、筋肉増強用の医薬品組成物、医薬部外品組成物及び飲食品組成物などの形態をとり得る。 The composition for muscle enhancement can be used in various forms for the purpose of obtaining a muscle enhancement action. For example, you may utilize for various purposes, without adding a special process. When the muscle strengthening composition is used for oral use, the dosage form is not particularly limited, and may be in the form of, for example, a pharmaceutical composition for muscle strengthening, a quasi-drug composition, and a food or drink composition.
飲食品組成物の具体的な一態様は、例えば、生体に対して一定の機能性を有する飲食品である機能性飲食品である。機能性飲食品は、例えば、特定保健用飲食品、機能性表示飲食品、栄養機能飲食品、保健機能飲食品、特別用途飲食品、栄養補助飲食品、健康補助飲食品、サプリメント、美容飲食品などのいわゆる健康飲食品に加えて、乳児用飲食品、妊産婦用飲食品、高齢者用飲食品などの特定者用飲食品を包含する。さらに機能性飲食品は、コーデックス(FAO/WHO合同食品規格委員会)の食品規格に基づく健康強調表示(Health claim)が適用される健康飲食品を包含する。 The specific one aspect | mode of the food-drinks composition is a functional food-drinks which are food-drinks which have fixed functionality with respect to a biological body, for example. Functional foods and beverages include, for example, specific health foods and drinks, functional indication foods and drinks, nutritional functional foods and drinks, health functional foods and drinks, special purpose foods and beverages, nutritional supplements and foods, health supplements and foods, supplements, and beauty foods and beverages. In addition to so-called healthy foods and beverages such as foods and beverages for infants, foods and beverages for pregnant women, foods and beverages for specific people such as foods and beverages for elderly people are included. Furthermore, functional food / beverage products include the health food / beverage products to which the health claim based on the food standards of Codex (FAO / WHO Joint Food Standards Committee) is applied.
筋肉増強用組成物の摂取量は特に限定されず、摂取者に求められる筋肉量の程度や摂取態様などに応じて適宜設定され得るが、例えば、摂取1回量として、摂取者の体重を基準として、HMB及び/又はその塩並びに上記態様(1)〜(3)の副成分の総量について10〜10,000mg/kg、好ましくは10〜1,000mg/kgである。 The amount of intake of the composition for muscle enhancement is not particularly limited, and can be appropriately set according to the degree of muscle mass required by the intake person, the intake mode, and the like. As for the total amount of HMB and / or a salt thereof and subcomponents of the above embodiments (1) to (3), it is 10 to 10,000 mg / kg, preferably 10 to 1,000 mg / kg.
筋肉増強用組成物の1日の摂取量は特に限定されず、例えば、HMB及び/又はその塩並びに上記態様(1)〜(3)の副成分の総量について1〜10g、好ましくは1.5〜4gである。 The daily intake of the muscle strengthening composition is not particularly limited. For example, the total amount of HMB and / or a salt thereof and the subcomponents of the above aspects (1) to (3) is 1 to 10 g, preferably 1.5. ~ 4g.
上述したとおり、筋肉増強用組成物の利用形態は特に限定されないが、例えば、経口用筋肉増強用組成物とすることができる。経口用筋肉増強用組成物の形態は特に限定されず、任意の形態とすることができる。経口用筋肉増強用組成物の形態としては、例えば、経口摂取に適した形態、具体的には液状、粉末状、粒状、顆粒状、錠状、棒状、板状、ブロック状、固形状、丸状、ペースト状、ハードカプセルやソフトカプセルのようなカプセル状、カプレット状、タブレット状、ゲル状などの各形態が挙げられる。 As described above, the usage form of the muscle strengthening composition is not particularly limited. For example, it can be an oral muscle strengthening composition. The form of the composition for enhancing muscle for oral use is not particularly limited, and can be any form. As the form of the composition for enhancing muscle for oral use, for example, a form suitable for oral intake, specifically, liquid, powder, granule, granule, tablet, rod, plate, block, solid, round Shapes, paste shapes, capsule shapes such as hard capsules and soft capsules, caplet shapes, tablet shapes, and gel shapes.
筋肉増強用組成物は、容器に詰めて密封した容器詰組成物とすることができる。容器は特に限定されないが、例えば、アルミなどの金属、紙、PETやPTPなどのプラスチック、1層又は積層(ラミネート)のフィルム袋、レトルトパウチ、真空パック、アルミ容器、プラスチック容器、瓶、缶などの包装容器が挙げられる。筋肉増強用組成物は、経時的な変質を避けるために、容器に詰めて密封した後に、加圧及び/又は加熱などにより殺菌処理したものであることが好ましい。 The composition for strengthening muscles can be a container-packed composition filled in a container and sealed. Although the container is not particularly limited, for example, metal such as aluminum, paper, plastic such as PET or PTP, single layer or laminated film bag, retort pouch, vacuum pack, aluminum container, plastic container, bottle, can, etc. The packaging container is mentioned. In order to avoid deterioration over time, the muscle building composition is preferably sterilized by pressurization and / or heating after being packed in a container and sealed.
筋肉増強用組成物の使用方法は特に限定されないが、例えば、筋肉増強用組成物をそのまま、水などとともに、又は水などで希釈するなどして、飲むことにより経口摂取することができる。摂取者の好みなどに応じて、筋肉増強用組成物と他の固体物や液状物とを混ぜて経口摂取してもよい。筋肉増強用組成物を口腔崩壊剤形とした場合は、水なしで経口摂取することができる。 Although the usage method of the composition for muscle enhancement is not specifically limited, For example, the composition for muscle enhancement can be orally ingested by drinking as it is with water etc. or diluting with water etc. as it is. Depending on the taste of the user, the composition for muscle strengthening and other solid or liquid materials may be mixed and taken orally. When the composition for enhancing muscle is made into an orally disintegrating dosage form, it can be taken orally without water.
筋肉増強用組成物は、HMB及び/又はその塩と上記態様(1)〜(3)の副成分とを少なくとも含有すればよいが、これらとその他の成分とを組み合わせたものとすることができる。その他の成分としては特に限定されないが、例えば、増粘剤、光沢剤、製造用剤などをその他の成分として用いることができる。これら以外にも、種々の賦形剤、結合剤、滑沢剤、安定剤、希釈剤、増量剤、乳化剤、着色料、香料、香油などをその他の成分として用いることができる。その他の成分の含有量は、筋肉増強用組成物の形態などに応じて適宜選択することができる。 The composition for muscle enhancement should just contain HMB and / or its salt and the subcomponent of said aspect (1)-(3) at least, However, These can be combined with another component. . Although it does not specifically limit as another component, For example, a thickener, a brightener, a manufacturing agent, etc. can be used as another component. In addition to these, various excipients, binders, lubricants, stabilizers, diluents, extenders, emulsifiers, colorants, fragrances, perfume oils and the like can be used as other components. The content of other components can be appropriately selected according to the form of the composition for enhancing muscles.
筋肉増強用組成物を非経口用組成物とする場合、例えば、化粧品に適した形態として使用することができる。すなわち、筋肉増強用組成物の一態様は、化粧用組成物である。例えば、筋肉増強用組成物は、そのままで、又は通常化粧品の加工に使用される添加物と混合して、ローション剤、乳剤、ゲル剤、クリーム剤、軟膏剤などの種々の形態に加工され得る。具体的には、化粧水、化粧クリーム、乳液、クリーム、パック、ヘアトニック、ヘアクリーム、シャンプー、ヘアリンス、トリートメント、洗顔剤、ファンデーション、育毛剤、水性軟膏、スプレーなどとして利用できる。 When the composition for enhancing muscle is used as a parenteral composition, it can be used in a form suitable for cosmetics, for example. That is, one aspect of the composition for enhancing muscles is a cosmetic composition. For example, the muscle building composition can be processed into various forms such as lotions, emulsions, gels, creams, ointments, etc., as they are or mixed with additives usually used in cosmetic processing. . Specifically, it can be used as a lotion, cosmetic cream, milky lotion, cream, pack, hair tonic, hair cream, shampoo, hair rinse, treatment, facial cleanser, foundation, hair restorer, aqueous ointment, spray and the like.
筋肉増強用組成物は、その筋肉増強作用により、これを使用することは、歩行困難者、運動障害者などの筋機能の低下によってもたらされる症状や疾患に罹患する者及びそのリスクがある者、直接的及び間接的に筋機能の低下に起因するその他の疾患に罹患する者及びそのリスクがある者に対しての健康維持に有用である。また、筋肉増強用組成物は、筋肉の衰えを感じる中高年者や運動不足者だけでなく、筋肉量増大、筋力上昇、シェイプアップ、身体の引き締め、痩身、トレーニング時の効率的な栄養の摂取などの要望をもつ若年者にとっても有用である。 The composition for muscle strengthening is due to its muscle strengthening action, so that it is possible to use it for those suffering from symptoms or diseases caused by a decrease in muscle function, such as those with difficulty walking and those with movement disorders, and those who are at risk. It is useful for maintaining health for persons suffering from and at risk of other diseases caused directly and indirectly by reduced muscle function. In addition, the composition for muscle strengthening is not only for middle-aged and elderly people who feel muscle weakness and those who lack exercise, but also increases muscle mass, muscle strength, shape up, body tightening, slimming, efficient nutrition intake during training, etc. It is also useful for young people with the needs of
以下、本発明を実施例によりさらに詳細に説明するが、本発明はこれら実施例に限定されるものではなく、本発明の課題を解決し得る限り、本発明は種々の態様をとることができる。 Hereinafter, the present invention will be described in more detail with reference to examples. However, the present invention is not limited to these examples, and the present invention can take various modes as long as the problems of the present invention can be solved. .
以下のとおりに、β−ヒドロキシ−β−メチル酪酸(HMB)と副成分との組み合わせによる、筋芽細胞の分化マーカーであるミオゲニン(Myogenin;Myog)の発現促進量を評価した。 As described below, the expression promotion amount of myogenin (Myogin), which is a differentiation marker of myoblasts, was evaluated by a combination of β-hydroxy-β-methylbutyric acid (HMB) and accessory components.
(1)被験物質
被験物質として以下のものを用いた。
・HMB:市販のHMBカルシウム
・赤ワイン:市販の赤ワイン抽出物(赤ワインの搾りかすのエタノール抽出物を噴霧乾燥したもの)
・黒ショウガ:市販の黒ショウガ抽出物(黒ショウガのエタノール抽出物を噴霧乾燥したもの)
・オルニチン:市販のL−オルニチン塩酸塩
(1) Test substances The following were used as test substances.
・ HMB: Commercially available HMB calcium ・ Red wine: Commercially available red wine extract (a spray-dried ethanol extract of red wine pomace)
・ Black ginger: Commercially available black ginger extract (Black ginger ethanol extract spray-dried)
Ornithine: Commercially available L-ornithine hydrochloride
0.5vol%DMSOを含有する2vol%Horse Serum−DMEM(2%HS−DMEM)分化誘導培地(0.5%DMSO−2%HS−DMEM)を溶媒として、被験物質を下記に示す所定濃度になるように溶解することにより被験物質溶液を調製した。
HMB 1000μg/mL
赤ワイン 6.25μg/mL
黒ショウガ 6.25μg/mL
オルニチン 50μg/mL
Using 2 vol% Horse Serum-DMEM (2% HS-DMEM) differentiation induction medium (0.5% DMSO-2% HS-DMEM) containing 0.5 vol% DMSO as a solvent, the test substance was adjusted to the prescribed concentrations shown below. A test substance solution was prepared by dissolving as follows.
HMB 1000μg / mL
Red wine 6.25μg / mL
Black ginger 6.25μg / mL
Ornithine 50 μg / mL
(2)被験試料
被験物質の最終濃度が50μg/mLになるように、被験物質溶液を0.5%DMSO−2%HS−DMEMに加えて、表1(単位はμg/mL)に示す被験試料を調製した。
(3)細胞培養
37℃、5%CO2インキュベーター内で、10vol%FBS−DMEM培地を入れた75cm2フラスコを用いて、マウス骨格筋由来細胞株C2C12を培養した。
(3) Cell culture The mouse skeletal muscle-derived cell line C2C12 was cultured in a 75 cm 2 flask containing 10 vol% FBS-DMEM medium at 37 ° C in a 5% CO 2 incubator.
培養後、トリプシン処理により浮遊させた細胞を75cm2フラスコから回収し、細胞数を計測した後、コラーゲンコートした96ウェルプレートの各ウェルに2,000cells/ウェルの細胞密度にて播種した。細胞を播種した96ウェルプレートを、37℃、5%CO2インキュベーター内で72時間培養した。 After culturing, cells suspended by trypsin treatment were collected from a 75 cm 2 flask, the number of cells was counted, and then seeded at a cell density of 2,000 cells / well in each well of a collagen-coated 96-well plate. The 96-well plate seeded with the cells was cultured in a 37 ° C., 5% CO 2 incubator for 72 hours.
培養後、ウェル内の培地を取り除き、各ウェルに2%HS−DMEM 200μLを加えて洗浄した。洗浄後の各ウェルに、被験試料1〜8を加えて、37℃、5%CO2インキュベーター内で24時間培養した。コントロールとして、被験試料を含まない0.5%DMSO−2%HS−DMEM、分化誘導をかけないネガティブコントロールとして、10%FBS−DMEMを添加して培養した。 After the culture, the medium in the well was removed, and 200 μL of 2% HS-DMEM was added to each well for washing. Test samples 1 to 8 were added to each well after washing, and cultured in a 37 ° C., 5% CO 2 incubator for 24 hours. As a control, 0.5% DMSO-2% HS-DMEM not containing a test sample was added, and 10% FBS-DMEM was added as a negative control without induction of differentiation.
(4)遺伝子発現解析
培養後、培地を除去し、各ウェルをPBS 200μL/ウェルで1回洗浄した。次いで、RNeasy Mini Kit(キアゲン社)を用いてmRNAを回収し、ReverTra Ace(登録商標) qPCR RT Master Mix with gDNA Remover(東洋紡社)を用いてcDNAを作製した。
(4) Gene expression analysis After the culture, the medium was removed, and each well was washed once with 200 μL / well of PBS. Subsequently, mRNA was collected using RNeasy Mini Kit (Qiagen), and cDNA was prepared using RiverTra Ace (registered trademark) qPCR RT Master Mix with gDNA Remover (Toyobo).
得られたcDNAを鋳型として、下記のプライマー(キアゲン社)を用いて、QuantiNova SYBR Green PCR Kit(キアゲン社)により定量リアルタイムPCRを行い、Gapdh及びミオゲニンのmRNA発現量を測定した。
Gapdh:Mm_Gapdh_3_SG QuantiTect Primer Assay (QT01658692)
Myog:Mm_Myog_1_SG QuantiTect Primer Assay (QT00112378)
Quantitative real-time PCR was performed using the obtained cDNA as a template and QuantiNova SYBR Green PCR Kit (Qiagen) using the following primers (Qiagen), and the mRNA expression levels of Gapdh and myogenin were measured.
Gapdh: Mm_Gapdh_3_SG QuantiTect Primer Assay (QT01665892)
Myog: Mm_Myog_1_SG QuantiTect Primer Assay (QT00112378)
解析は相対定量により行い、GapdhのmRNA発現量を内在性コントロールとしてmRNA量を補正した。 Analysis was carried out by relative quantification, and the amount of mRNA was corrected using the amount of Gapdh mRNA expressed as an endogenous control.
(5)評価
HMBと副成分との組み合わせによる、ミオゲニンのmRNA発現量の測定結果(内在性コントロールに対する相対発現量)を比較例1の値を1にした時の相対値として図1に示す。
(5) Evaluation The measurement result of the myogenin mRNA expression level (relative expression level relative to the endogenous control) by the combination of HMB and subcomponents is shown in FIG. 1 as a relative value when the value of Comparative Example 1 is 1.
図1に示されているとおりに、HMB単独よりも、HMBと赤ワイン、及び黒ショウガといった副成分とを組み合わせた方が、ミオゲニン発現量は大きかった。 As shown in FIG. 1, the myogenin expression level was greater when HMB was combined with subcomponents such as red wine and black ginger than with HMB alone.
そして、驚くべきことに、HMBと赤ワイン、又は黒ショウガとの組み合わせによる発現量からHMB単独の発現量を差し引いて得られる発現量に基づけば、HMBと組み合わせるべき副成分を、1種類よりも、2種類にすることにより、相加的よりもむしろ相乗的にミオゲニン発現量は大きくなった。 And surprisingly, based on the expression level obtained by subtracting the expression level of HMB alone from the expression level of the combination of HMB and red wine or black ginger, the subcomponents to be combined with HMB are more than one type. By using two types, the myogenin expression level increased synergistically rather than additively.
さらに、HMBと単独で組み合わせてもミオゲニンの発現量に影響しなかったオルニチンを、黒ショウガ、若しくは赤ワインの何れか、又はそれらの両方と組み合わせることで、ミオゲニンの発現量が飛躍的に増大した。 Furthermore, the expression level of myogenin increased dramatically by combining ornithine, which did not affect the expression level of myogenin when combined with HMB alone, with either black ginger, red wine, or both.
以上の結果から、HMBは、赤ワイン、及び/又は黒ショウガと組み合わせることによって、ミオゲニンのmRNA発現量を促進すること、オルニチンはこの効果をさらに増強することがわかった。そして、このことより、これらの組み合わせは、筋芽細胞の分化誘導を促し、もって筋肉増強作用を有することがわかる。 From the above results, it was found that HMB promotes the myogenin mRNA expression level when combined with red wine and / or black ginger, and ornithine further enhances this effect. From this, it can be seen that these combinations promote the induction of myoblast differentiation and thus have a muscle strengthening action.
<製造例1〜6>
下記表2の配合にて、HMB及び赤ワイン、黒ショウガ、オルニチンを含有する顆粒剤を製造した。
Granules containing HMB, red wine, black ginger and ornithine were prepared according to the formulation shown in Table 2 below.
<製造例7〜12>
下記表3の配合にて、HMB及び赤ワイン、黒ショウガ、オルニチンを含有する顆粒剤を製造した。
Granules containing HMB, red wine, black ginger and ornithine were prepared according to the formulation shown in Table 3 below.
<製造例13〜18>
下記表4の配合にて、HMB及び赤ワイン、黒ショウガ、オルニチンを含有する粉末飲料を製造した。
A powdered beverage containing HMB, red wine, black ginger and ornithine was prepared according to the formulation shown in Table 4 below.
<製造例19〜24>
下記表5の配合にて、HMB及び赤ワイン、黒ショウガ、オルニチンを配合し、ゼラチン及びグリセリンを含む被膜で被包し、ソフトカプセル剤を製造した。
HMB, red wine, black ginger and ornithine were blended according to the blending shown in Table 5 below, and encapsulated with a film containing gelatin and glycerin to produce a soft capsule.
<製造例25〜30>
下記表6の配合にて、HMB及び赤ワイン、黒ショウガ、オルニチンを配合し、ゼラチンを含む被膜で被包し、ハードカプセル剤を製造した。
HMB, red wine, black ginger and ornithine were blended according to the blending shown in Table 6 below, followed by encapsulation with a film containing gelatin to produce a hard capsule.
<製造例31〜36>
下記表7の配合にて、HMB及び赤ワイン、黒ショウガ、オルニチンを含有する液体飲料を製造した。
A liquid beverage containing HMB, red wine, black ginger and ornithine was prepared according to the formulation shown in Table 7 below.
<製造例37〜42>
下記表8の配合にて、HMB及び赤ワイン、黒ショウガ、オルニチンを含有する錠剤を製造した。
Tablets containing HMB, red wine, black ginger and ornithine were prepared according to the formulation shown in Table 8 below.
本発明の一態様の筋肉増強用組成物は、筋肉増強作用を有することから、筋機能が低下した者、筋肉の衰えを感じる中高年者や運動不足者の健康維持に利用可能であるだけでなく、筋肉量増大、筋力上昇、身体の引き締めなどの要望をもつ若年者にとっても有用である。 Since the composition for enhancing muscles according to one aspect of the present invention has a muscle-enhancing effect, it can be used not only for maintaining the health of persons with reduced muscle function, middle-aged and older persons who feel muscle weakness, and those who lack exercise. It is also useful for young people who have demands for increased muscle mass, increased strength, and tightening the body.
Claims (3)
赤ワイン及びその抽出物、黒ショウガ及びその抽出物、並びにオルニチン及びその塩からなる群から選ばれる2種以上の成分と
を含有する、筋肉増強用組成物。 β-hydroxy-β-methylbutyric acid and / or a salt thereof;
A composition for enhancing muscle, comprising two or more components selected from the group consisting of red wine and its extract, black ginger and its extract, and ornithine and its salt.
赤ワイン及び/又はその抽出物と、
黒ショウガ及び/又はその抽出物と、
オルニチン及び/又はその塩と
を含有する、筋肉増強用組成物。 β-hydroxy-β-methylbutyric acid and / or a salt thereof;
Red wine and / or its extract;
Black ginger and / or its extract;
A composition for enhancing muscle, comprising ornithine and / or a salt thereof.
赤ワイン及びその抽出物、並びに黒ショウガ及びその抽出物のいずれか1種以上の成分と
を含有する、筋肉増強用組成物。 β-hydroxy-β-methylbutyric acid and / or a salt thereof;
A composition for strengthening muscle, comprising red wine and its extract, and one or more components of black ginger and its extract.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2016233127A JP2018090504A (en) | 2016-11-30 | 2016-11-30 | Muscle enhancing composition |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2016233127A JP2018090504A (en) | 2016-11-30 | 2016-11-30 | Muscle enhancing composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JP2018090504A true JP2018090504A (en) | 2018-06-14 |
Family
ID=62565237
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016233127A Pending JP2018090504A (en) | 2016-11-30 | 2016-11-30 | Muscle enhancing composition |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP2018090504A (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2019517576A (en) * | 2016-05-25 | 2019-06-24 | ティーエスアイ・グループ・リミテッド | Stabilization of beta-hydroxy isovaleric acid preparations in soft gel capsules |
| JP2020195286A (en) * | 2019-05-31 | 2020-12-10 | 株式会社東洋新薬 | Oral composition |
| WO2021200996A1 (en) * | 2020-03-30 | 2021-10-07 | 味の素株式会社 | Composition for ameliorating or preventing decreases in bone strength |
| WO2022145438A1 (en) | 2020-12-28 | 2022-07-07 | ヤマサ醤油株式会社 | PGC-1α EXPRESSION PROMOTING AGENT, MUSCLE-BUILDING AGENT, AND MITOCHONDRIA ACTIVATING AGENT |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007077995A1 (en) * | 2006-01-05 | 2007-07-12 | Kyowa Hakko Kogyo Co., Ltd. | Muscle-building agent |
| JP2014506254A (en) * | 2010-12-27 | 2014-03-13 | アボット・ラボラトリーズ | Method for promoting muscle recovery after a disuse period using β-hydroxy-β-methylbutyrate |
| JP2015010078A (en) * | 2013-07-01 | 2015-01-19 | 日本タブレット株式会社 | Muscle mass increasing agent |
| WO2015137387A1 (en) * | 2014-03-11 | 2015-09-17 | 協和発酵バイオ株式会社 | Muscle enhancing drug |
| JP5903191B2 (en) * | 2012-05-16 | 2016-04-13 | 丸善製薬株式会社 | Use of Kemperia parwiflora extract or flavone compounds to prevent or treat muscle diseases and improve muscle function |
-
2016
- 2016-11-30 JP JP2016233127A patent/JP2018090504A/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007077995A1 (en) * | 2006-01-05 | 2007-07-12 | Kyowa Hakko Kogyo Co., Ltd. | Muscle-building agent |
| JP2014506254A (en) * | 2010-12-27 | 2014-03-13 | アボット・ラボラトリーズ | Method for promoting muscle recovery after a disuse period using β-hydroxy-β-methylbutyrate |
| JP5903191B2 (en) * | 2012-05-16 | 2016-04-13 | 丸善製薬株式会社 | Use of Kemperia parwiflora extract or flavone compounds to prevent or treat muscle diseases and improve muscle function |
| JP2015010078A (en) * | 2013-07-01 | 2015-01-19 | 日本タブレット株式会社 | Muscle mass increasing agent |
| WO2015137387A1 (en) * | 2014-03-11 | 2015-09-17 | 協和発酵バイオ株式会社 | Muscle enhancing drug |
Non-Patent Citations (5)
| Title |
|---|
| 【公式】マッスルエレメンツ|高純度国産HMBサプリ-初回500円/全額返金保証付き, P.1-45, JPN6020000793, ISSN: 0004268647 * |
| DIABATE(710TH SCIENTIFIC SESSIONS OF AMERICAN DIABATES ASSOSIATION), 2010, P.1(ABSTRACT NUMBER 2565-, JPN6020000787, ISSN: 0004268644 * |
| NUTRITION, 2013, VOL.29, P.29-36, JPN6020000785, ISSN: 0004268643 * |
| 株式会社SELMORE, NEWS 新着情報, (HTTPS://SELMORE.BIZ/), JPN6020000792, ISSN: 0004268646 * |
| 第68回日本栄養・食糧学会大会講演要旨集, 2014, P.267(3H-05P), JPN6020000790, ISSN: 0004268645 * |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2019517576A (en) * | 2016-05-25 | 2019-06-24 | ティーエスアイ・グループ・リミテッド | Stabilization of beta-hydroxy isovaleric acid preparations in soft gel capsules |
| JP2020195286A (en) * | 2019-05-31 | 2020-12-10 | 株式会社東洋新薬 | Oral composition |
| WO2021200996A1 (en) * | 2020-03-30 | 2021-10-07 | 味の素株式会社 | Composition for ameliorating or preventing decreases in bone strength |
| WO2022145438A1 (en) | 2020-12-28 | 2022-07-07 | ヤマサ醤油株式会社 | PGC-1α EXPRESSION PROMOTING AGENT, MUSCLE-BUILDING AGENT, AND MITOCHONDRIA ACTIVATING AGENT |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6714928B2 (en) | Collagenase inhibitor | |
| TW200529864A (en) | Method for producing maca extract | |
| JP2017141199A (en) | Liver function improving agent | |
| JP2018090504A (en) | Muscle enhancing composition | |
| EP1945046A1 (en) | Method of obtaining a plant extract from pome fruit, plant extract thus obtained and use of same | |
| JP6482930B2 (en) | Skin cosmetics and foods and drinks | |
| TWI225789B (en) | Compositions inhibiting muscle atrophy | |
| JP2010095529A (en) | Composition for improving lipid metabolism | |
| KR20210080182A (en) | Composition for preventing and treating of obesity comprising powder of lactic acid cell lysate | |
| TW202317166A (en) | Uses of golden passion fruit ferment for improving skin condition and anti-photoaging | |
| JP2002047193A (en) | Composition for preventing or treating allergic dermatitis | |
| JP7535333B2 (en) | Oral Compositions | |
| CN110913833B (en) | Whitening composition comprising quercetin compounds | |
| JP2021113172A (en) | Peptidyl arginine deiminase 1 expression promoter | |
| WO2005094860A1 (en) | Agent improving peripheral blood flow | |
| WO2005094859A1 (en) | Agent improving moisture-retention function of skin | |
| JP5582593B2 (en) | Platelet aggregation inhibitor | |
| JPH09315987A (en) | Utilization of awamori as antiallergic active ingredient | |
| JP6774065B2 (en) | Blood flow improver | |
| CN109619577A (en) | The application of Rosa roxburghii Tratt water extract | |
| JP2008013531A (en) | Collagen production promoter and food and beverage for beauty containing the same | |
| JP2023509324A (en) | Composition for prevention, improvement or treatment of atopic dermatitis disease | |
| JP7090864B2 (en) | Composition | |
| TWI892031B (en) | Use of redlove apples extract for improving skin condition | |
| TWI653989B (en) | a composition comprising an herbal extract obtained by processing oriental herbs |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20191128 |
|
| A871 | Explanation of circumstances concerning accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A871 Effective date: 20191128 |
|
| A975 | Report on accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A971005 Effective date: 20191211 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20200121 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200317 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20200526 |